Through analysis of the transcriptome expression profiles of public databases and study on available clinical samples and GBM cell lines, we found that CD2AP expression was significantly upregulated in GBM samples compared to non-tumor and low-grade glioma samples. This evidence concerns the gene CD2AP and glioblastoma.